BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21146434)

  • 1. 2,4-Diamino-5-(2'-arylpropargyl)pyrimidine derivatives as new nonclassical antifolates for human dihydrofolate reductase inhibition.
    Algul O; Paulsen JL; Anderson AC
    J Mol Graph Model; 2011 Feb; 29(5):608-13. PubMed ID: 21146434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
    Gangjee A; Jain HD; Phan J; Guo X; Queener SF; Kisliuk RL
    Bioorg Med Chem; 2010 Jan; 18(2):953-61. PubMed ID: 20056546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
    Gangjee A; Jain HD; Queener SF; Kisliuk RL
    J Med Chem; 2008 Aug; 51(15):4589-600. PubMed ID: 18605720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
    J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2002 Jan; 45(1):233-41. PubMed ID: 11754594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.
    Wang M; Yang J; Yuan M; Xue L; Li H; Tian C; Wang X; Liu J; Zhang Z
    Eur J Med Chem; 2017 Mar; 128():88-97. PubMed ID: 28152430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating features that drive the design of selective antifolates using crystal structures of human dihydrofolate reductase.
    Lamb KM; G-Dayanandan N; Wright DL; Anderson AC
    Biochemistry; 2013 Oct; 52(41):7318-26. PubMed ID: 24053334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.
    Li H; Fang F; Liu Y; Xue L; Wang M; Guo Y; Wang X; Tian C; Liu J; Zhang Z
    Bioorg Med Chem; 2018 May; 26(9):2674-2685. PubMed ID: 29691154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
    Gangjee A; Shi J; Queener SF; Barrows LR; Kisliuk RL
    J Med Chem; 1993 Oct; 36(22):3437-43. PubMed ID: 8230134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.
    Cody V; Galitsky N; Luft JR; Pangborn W; Queener SF; Gangjee A
    Acta Crystallogr D Biol Crystallogr; 2002 Sep; 58(Pt 9):1393-9. PubMed ID: 12198294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
    Cody V; Pace J; Chisum K; Rosowsky A
    Proteins; 2006 Dec; 65(4):959-69. PubMed ID: 17019704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates.
    Gangjee A; Yang J; McGuire JJ; Kisliuk RL
    Bioorg Med Chem; 2006 Dec; 14(24):8590-8. PubMed ID: 16990006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity correlations for three pyrido[2,3-d]pyrimidine antifolates binding to human and Pneumocystis carinii dihydrofolate reductase.
    Cody V; Pace J; Namjoshi OA; Gangjee A
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):799-803. PubMed ID: 26057816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
    Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
    J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
    Gao T; Zhang C; Shi X; Guo R; Zhang K; Gu J; Li L; Li S; Zheng Q; Cui M; Cui M; Gao X; Liu Y; Wang L
    Eur J Med Chem; 2019 Sep; 178():329-340. PubMed ID: 31200235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.